☆ 4.7 Review

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis

Fabio Turco et al.

Summary: This retrospective study evaluated the prognostic role of treatment discontinuation due to adverse events in mCRPC patients treated with Ra-223. The study found that discontinuation due to toxicity was associated with worse outcomes. The number of previous treatments, previous chemotherapy treatment, baseline LDH, Hb, and PLR were identified as factors correlated with the risk of Ra-223 discontinuation due to toxicity.

TUMORI JOURNAL (2023)

Add to Collection

Article Oncology

Recent Advances in the Management of Metastatic Prostate Cancer

Soo Yeon Kim et al.

Summary: The management of metastatic prostate cancer has undergone a revolution with the introduction of new agents and the repurposing of existing ones. These novel therapies have shown improved outcomes and have received approval. The ongoing investigation of multiple new agents is expected to further improve survival outcomes for patients in the coming years.

JCO ONCOLOGY PRACTICE (2022)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

V Subbiah et al.

Summary: This study evaluated the efficacy and safety of dabrafenib plus trametinib in the treatment of BRAF V600E-mutant ATC. The results showed that the combination therapy provided significant clinical benefits and manageable toxicity, leading to improved long-term survival in patients with ATC.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Oncology

Nivolumab plus docetaxel in patients with chemotherapy- nai spacing diaeresis ve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial

Karim Fizazi et al.

Summary: Nivolumab plus docetaxel demonstrated clinical activity in chemotherapy-naive mCRPC patients, with improved objective response rate and prostate-specific antigen response rate, and acceptable safety profile.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Patrick Y. Wen et al.

Summary: The study evaluated the efficacy and safety of dabrafenib plus trametinib in patients with high-grade glioma and low-grade glioma who had BRAF(V600E) mutation. The results showed that dabrafenib plus trametinib demonstrated meaningful activity in the treatment of recurrent or refractory high-grade glioma and low-grade glioma with BRAF(V600E) mutation, and had a safety profile consistent with other indications.

LANCET ONCOLOGY (2022)

Add to Collection

Review Oncology

The Essentials of Multiomics

John L. Marshall et al.

Summary: This paper discusses the development and importance of multiomics in clinical practice, highlighting the knowledge gap within the medical community and urging physicians to actively adapt and prepare for this new era.

ONCOLOGIST (2022)

Add to Collection

Article Urology & Nephrology

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Evan Y. Yu et al.

Summary: The study evaluated the efficacy and safety of pembrolizumab combined with docetaxel and prednisone in patients with mCRPC, showing promising antitumor activity and manageable safety in this patient population.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review

Giovanni Maria Iannantuono et al.

Summary: This study evaluated the activity of ALK inhibitors in ALK-rearranged renal cell carcinoma (ALK-RCC) and found that first- and second-generation ALK inhibitors showed favorable activity in pretreated ALK-RCC patients in terms of radiological response and performance status improvement. The results suggest the potential of ALK inhibitors as a targeted therapy for ALK-RCC.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies

Joanna Cyrta et al.

Summary: This study compares the pathological and molecular features of primary prostate cancer (PCa) and metastases, revealing their heterogeneity. The results highlight the importance of comprehensive immunohistochemistry-assisted pathology review and genomic analysis in determining the "index" area of primary PCa.

JOURNAL OF PATHOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Delivering precision oncology to patients with cancer

Joaquin Mateo et al.

Summary: Precision medicine is reshaping cancer care, but accessibility to all patients remains a challenge. This Perspective highlights the importance of addressing the challenges in implementing precision oncology, including equal access to genomics tests, robust evidence for new drugs and technologies, interpretation of genomics data by physicians, and empowering patients in shared decision-making.

NATURE MEDICINE (2022)

Add to Collection

Review Endocrinology & Metabolism

Mismatch repair deficiency and clinical implications in prostate cancer

Laura S. Graham et al.

Summary: Mismatch repair deficiency (MMRd) is an important predictive biomarker for response to immune checkpoint blockade in various tumor types, including prostate cancer. Pembrolizumab, a checkpoint inhibitor, has shown promising results in MMRd prostate cancer.

PROSTATE (2022)

Add to Collection

Article Genetics & Heredity

Correlation of NTRK1 Downregulation with Low Levels of Tumor-Infiltrating Immune Cells and Poor Prognosis of Prostate Cancer Revealed by Gene Network Analysis

Arash Bagherabadi et al.

Summary: This study identified the prognostic gene NTRK1 in prostate cancer using bioinformatics analysis, and found that downregulation of NTRK1 is associated with poor prognosis and increased levels of immune cells.

GENES (2022)

Add to Collection

Article Oncology

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives

Sara Elena Rebuzzi et al.

Summary: This review evaluates the potential role of immunotherapy in advanced prostate cancer and discusses the immunobiology of PCa, ongoing trials, and available clinical data. It suggests that immunotherapy may be effective in certain subsets of patients and highlights the importance of further research in identifying predictive biomarkers and exploring new therapeutic targets.

CANCERS (2022)

Add to Collection

Article Medicine, General & Internal

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer

Ryon P. Graf et al.

Summary: This study compared the treatment outcomes of immune checkpoint inhibitors (ICI) and taxane chemotherapy in mCRPC patients based on tumor mutational burden (TMB). The results showed that ICI was more effective than taxanes in patients with high TMB, but not in those with low TMB.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Medicine, Research & Experimental

A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months

Kosuke Shimizu et al.

Summary: Defective DNA mismatch repair genes can lead to microsatellite instability in prostate cancer, and this status could be a target for immune checkpoint inhibitors. This case study presents a patient with microsatellite instability castration-resistant prostate cancer who showed a remarkable and durable response to pembrolizumab.

COLD SPRING HARBOR MOLECULAR CASE STUDIES (2022)

Add to Collection

Review Oncology

Applicability of ESMO-MCBS and ESCAT for molecular tumor boards

Ladislaia Wolff et al.

Summary: This review summarizes the current status and applicability of scoring systems for genomic alterations (GAs) in molecular tumor boards, including the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) and the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS).

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors

Leigh Marcus et al.

Summary: Entrectinib is approved by FDA for treating solid tumors with NTRK gene fusions, showing a durable overall response rate with potential toxicities including congestive heart failure and central nervous system effects.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Prevalence of comprehensiveDNAdamage repair gene germline mutations in Chinese prostate cancer patients

Junlong Wu et al.

Summary: This study provides a comprehensive view of germline DDR gene mutations in PCa patients and identifies two potential PCa predisposition genes, POLN and POLG, not previously reported in the Western population, highlighting the necessity of customizing a multigene panel for Chinese PCa patients.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Medicine, Research & Experimental

Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade

Laura A. Sena et al.

Summary: Parenchymal brain metastases from prostate cancer are rare and have a poor prognosis, with limited understanding of their molecular and histologic characteristics. A patient with metastatic castration-resistant, mismatch repair-deficient prostate cancer received immune checkpoint blockade therapy, showing an enhanced immune response in brain metastases post-treatment.

COLD SPRING HARBOR MOLECULAR CASE STUDIES (2021)

Add to Collection

Editorial Material Oncology

The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies

Yonina R. Murciano-Goroff et al.

Summary: The NCI-MATCH trial, published in the Journal of Clinical Oncology, demonstrates the feasibility of identifying rare and common actionable genetic alterations, highlighting the strength of academic/community partnerships for improving trial access.

CANCER CELL (2021)

Add to Collection

Article Oncology

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?

John H. Strickler et al.

Summary: While high tumor mutational burden (TMB-H) has shown promise as a biomarker in lung cancer, its broad applicability across all solid tumors is unclear. The FDA has approved the PD-1 inhibitor, pembrolizumab, as a therapy for all solid tumors with TMB equal to or greater than 10 mutations. However, there are risks and unanswered questions regarding the use of TMB as a biomarker.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer

Laura A. Sena et al.

Summary: In patients with DNA mismatch repair-deficient prostate cancer, tumor frameshift mutation proportion (FSP) is correlated with response to anti-PD1 therapy.

ONCOLOGIST (2021)

Add to Collection

Review Oncology

The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality

Paolo Tarantino et al.

Summary: Precision medicine is changing oncology through the identification of biomarkers predictive of treatment response in cancer patients. Several biomarkers, including NTRK fusions, microsatellite instability, and high tumor mutational burden, have been approved regardless of tumor histology, indicating a histology-agnostic approach. However, histology-agnosticism is seen as a spectrum of actionability rather than a binary quality according to available evidence.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Review Oncology

Immune Checkpoint Inhibitors in Prostate Cancer

Shobi Venkatachalam et al.

Summary: Metastatic prostate cancer is a lethal disease with limited treatment options. Immune checkpoint inhibitors have revolutionized the treatment landscape in various cancer types, but have not been as successful in prostate cancer. This review discusses the preclinical rationale and barriers inhibiting the effectiveness of immunotherapy in prostate cancer, as well as the ongoing studies evaluating the use of immune checkpoint inhibitors in combination with other agents to improve treatment outcomes.

CANCERS (2021)

Add to Collection

Article Oncology

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors

Leigh Marcus et al.

Summary: The FDA approved pembrolizumab for the treatment of TMB-H solid tumors in adults and children, based on its significant overall response rate and duration in clinical trials. This marks the first FDA approval of a cancer treatment based on TMB, and the fourth based on a biomarker rather than primary site.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Daniel P. Petrylak et al.

Summary: Pembrolizumab has shown activity in mCRPC patients as monotherapy and in combination with docetaxel and prednisone/prednisolone. The Phase III KEYNOTE-921 study aims to evaluate the efficacy and safety of pembrolizumab plus docetaxel in mCRPC patients previously treated with an NHA therapy, addressing the unmet need for treatment options in this patient population.

FUTURE ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets

Evangelia Ioannidou et al.

Summary: Prostate cancer is the most common cancer in men and despite therapeutic advances, many patients still cannot be cured. Antiagiogenic therapies have shown limited benefits for prostate cancer compared to other types of cancer. Clinical trials and treatments for refractory castration-resistant prostate cancer face challenges and further research is needed to better understand mechanisms of resistance.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Medicine, General & Internal

Prostate cancer

Shahneen Sandhu et al.

Summary: Management of prostate cancer is rapidly evolving with advances in understanding the genomic landscape, improved imaging methods, and personalised therapeutics targeting DNA repair pathways. The therapeutic framework for metastatic disease has shifted, with oligometastatic disease being evaluated for metastatic-directed therapies, and novel androgen pathway inhibitors showing significant survival benefits as first-line therapy for metastatic disease. Emerging research into molecular characterisation and novel therapeutics, such as targeted radioisotopes and immunotherapy, hold promise for improving patient outcomes.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor et al.

Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Oncology

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Carlo Cattrini et al.

Summary: For patients with advanced prostate cancer, various treatment options such as chemotherapy, androgen-receptor signaling inhibitors, and radium-223 have significantly improved survival rates. However, the optimal sequencing of these treatments remains unclear, highlighting the need for further research to identify the best treatment approach for patients at different disease stages.

CANCERS (2021)

Add to Collection

Review Oncology

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Taobi Huang et al.

Summary: This study conducted a systematic review and meta-analysis to investigate whether tumor mutational burden (TMB) can be used as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors (ICIs). The results showed that high TMB patients receiving ICIs had significantly better overall survival (OS) and progression-free survival (PFS) compared to low TMB patients. TMB may serve as a promising independent prognostic biomarker for cancer patients undergoing immunotherapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

C. B. Westphalen et al.

Summary: NTRK gene fusions are rare oncogenic drivers in solid tumors, with a prevalence of 0.30% across various cancers and notable variations based on age, cancer type, and histology. Combining large datasets helps in better understanding the characteristics of these rare molecular subgroups of cancer, revealing unique genomic patterns and fusion partners. The presence of NTRK gene fusions did not correlate with other clinically actionable biomarkers, showing distinct genetic features in NTRK fusion-positive tumors.

NPJ PRECISION ONCOLOGY (2021)

Add to Collection

Review Oncology

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

Luiza N. Weis et al.

Summary: Precision medicine in oncology has brought new perspectives, focusing on targeted therapies across different tumor types without considering their site of origin. FDA has approved three agents for tumor-agnostic treatment, but the efficacy of these agents in breast cancer remains uncertain due to the rarity of their targeted genomic alterations.

NPJ BREAST CANCER (2021)

Add to Collection

Review Oncology

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer

A. Trullas et al.

Summary: The European Commission approved pembrolizumab for the first-line treatment of MSI-H or dMMR metastatic colorectal cancer in adults, leading to a significant improvement in progression-free survival compared to standard of care.

ESMO OPEN (2021)

Add to Collection

Article Oncology

Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series

Deepak Ravindranathan et al.

Summary: The US FDA has approved Pembrolizumab for the treatment of MSI-H or mismatch repair deficient solid tumors. Blood-based ctDNA assays can accurately identify tumors with MSI-H status. Two mCRPC patients treated with Pembrolizumab showed excellent clinical responses, including a significant reduction in somatic-variant allele frequency and decrease in prostate serum antigen levels detected by liquid biopsies.

CASE REPORTS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

From Tissue-Agnostic to N-of-One Therapies:(R)Evolution of the Precision Paradigm

Jacob J. Adashek et al.

Summary: Precision medicine has revolutionized the treatment of lethal cancers through next-generation sequencing and targeted drug deployment, highlighting the need for personalized treatments with drug combinations and customization. Real-world data and registry trials are expected to further drive the evolution of oncology.

TRENDS IN CANCER (2021)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

Microsatellite instability: a review of what the oncologist should know

Kai Li et al.

CANCER CELL INTERNATIONAL (2020)

Add to Collection

Article Oncology

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

Ezra Y. Rosen et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Eradication of BRAF K601E Mutation in Metastatic Castrate-resistant Prostate Cancer Treated With Cabazitaxel and Carboplatin: A Case Report

Peter Steinwald et al.

CLINICAL GENITOURINARY CANCER (2020)

Add to Collection

Article Oncology

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

Robert C. Doebele et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Variant analysis of prostate cancer in Japanese patients and a new attempt to predict related biological pathways

Rika Kasajima et al.

ONCOLOGY REPORTS (2020)

Add to Collection

Article Multidisciplinary Sciences

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies

Laura S. Graham et al.

PLOS ONE (2020)

Add to Collection

Article Medicine, General & Internal

Olaparib for Metastatic Castration-Resistant Prostate Cancer

J. de Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Cell Biology

Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases

Mohamed Alhamar et al.

HISTOPATHOLOGY (2020)

Add to Collection

Article Oncology

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA

Pedro Barata et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

April K. S. Salama et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Mismatch Repair Pathway, Genome Stability and Cancer

Nives Pecina-Slaus et al.

FRONTIERS IN MOLECULAR BIOSCIENCES (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape

Irene Vanni et al.

FRONTIERS IN MOLECULAR BIOSCIENCES (2020)

Add to Collection

Meeting Abstract Oncology

A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)

C. G. Drake et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Review Oncology

Histology-agnostic drug development - considering issues beyond the tissue

Roberto Carmagnani Pestana et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurelien Marabelle et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Vivek Subbiah et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Urology & Nephrology

Targetable gene fusions and aberrations in genitourinary oncology

Filippo Pederzoli et al.

NATURE REVIEWS UROLOGY (2020)

Add to Collection

Review Cell Biology

Is There a Role for Immunotherapy in Prostate Cancer?

Alessandro Rizzo et al.

CELLS (2020)

Add to Collection

Editorial Material Oncology

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies

Elena Ardini et al.

ESMO OPEN (2020)

Add to Collection

Review Cell Biology

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Wout Devlies et al.

CELLS (2020)

Add to Collection

Review Oncology

A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors

Anna Forsythe et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer

Harry J. Han et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Article Urology & Nephrology

Targeted next-generation sequencing for locally advanced prostate cancer in the Korean population

Jungyo Suh et al.

INVESTIGATIVE AND CLINICAL UROLOGY (2020)

Add to Collection

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Letter Dermatology

Dabrafenib plus trametinib in BRAF K601E-mutant melanoma

A. Rogiers et al.

BRITISH JOURNAL OF DERMATOLOGY (2019)

Add to Collection

Article Oncology

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

Leigh Marcus et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

Piper Nicolosi et al.

JAMA ONCOLOGY (2019)

Add to Collection

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment

Larissa Bastos Costa et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

Add to Collection

Article Multidisciplinary Sciences

Genomic correlates of clinical outcome in advanced prostate cancer

Wassim Abida et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Add to Collection

Article Oncology

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

C. Marchio et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

C. Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Oncology

Tumor mutational burden quantification from targeted gene panels: major advancements and challenges

Laura Fancello et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Review Oncology

Targeting Oncogenic BRAF: Past, Present, and Future

Aubhishek Zaman et al.

CANCERS (2019)

Add to Collection

Review Urology & Nephrology

Towards precision oncology in advanced prostate cancer

Sheng-Yu Ku et al.

NATURE REVIEWS UROLOGY (2019)

Add to Collection

Review Medicine, Research & Experimental

Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols

Jay J. H. Park et al.

TRIALS (2019)

Add to Collection

Review Oncology

Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications

Matthew J. Ryan et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Article Oncology

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing

Sadakatsu Ikeda et al.

CANCER BIOLOGY & THERAPY (2019)

Add to Collection

Article Urology & Nephrology

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations

Emmanuel S. Antonarakis et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Article Oncology

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

Alicia Latham et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer

Charlotte Manogue et al.

ONCOLOGIST (2019)

Add to Collection

Article Oncology

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

Wassim Abida et al.

JAMA ONCOLOGY (2019)

Add to Collection

Review Oncology

How I treat MSI cancers with advanced disease

Marleen Kok et al.

ESMO OPEN (2019)

Add to Collection

Article Biotechnology & Applied Microbiology

Issues and promises of bevacizumab in prostate cancer treatment

Vittore Cereda et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2018)

Add to Collection

Article Oncology

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

Vivek Subbiah et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

A. Drilon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Targeted Next-Generation Sequencing in Men with Metastatic Prostate Cancer: a Pilot Study

Pedro C. Barata et al.

TARGETED ONCOLOGY (2018)

Add to Collection

Article Oncology

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

J. Mateo et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

75PThe landscape of NTRK fusions in Chinese patients with solid tumor

Q Ling et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Review Oncology

NTRK fusion-positive cancers and TRK inhibitor therapy

Emiliano Cocco et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le et al.

SCIENCE (2017)

Add to Collection

Article Genetics & Heredity

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Zachary R. Chalmers et al.

GENOME MEDICINE (2017)

Add to Collection

Article Oncology

MSH2 Loss in Primary Prostate Cancer

Liana B. Guedes et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Medicine, General & Internal

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

C. C. Pritchard et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Oncology

Defining actionable mutations for oncology therapeutic development

T. Hedley Carr et al.

NATURE REVIEWS CANCER (2016)

Add to Collection

Review Oncology

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

Alessio Amatu et al.

ESMO OPEN (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Integrative Clinical Genomics of Advanced Prostate Cancer

Dan Robinson et al.

CELL (2015)

Add to Collection

Article Medicine, General & Internal

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Endocrinology & Metabolism

Molecular Profiling of ETS and Non-ETS Aberrations in Prostate Cancer Patients From Northern India

Bushra Ateeq et al.

PROSTATE (2015)

Add to Collection

Review Pharmacology & Pharmacy

Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches

Vittore Cereda et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)

Add to Collection

Review Oncology

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

Matthew Holderfield et al.

NATURE REVIEWS CANCER (2014)

Add to Collection

Article Medicine, General & Internal

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

C. Parker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Multidisciplinary Sciences

Comprehensive molecular characterization of human colon and rectal cancer

Donna M. Muzny et al.

NATURE (2012)

Add to Collection

Article Medicine, General & Internal

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Howard I. Scher et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. De Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Review Dermatology

BRAF inMelanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

Ryan J. Sullivan et al.

JOURNAL OF SKIN CANCER (2011)

Add to Collection

Article Oncology

KRAS and BRAF mutations in prostate carcinomas of Chinese patients

Yanying Shen et al.

CANCER GENETICS AND CYTOGENETICS (2010)

Add to Collection

Article Medicine, General & Internal

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Johann Sebastian de Bono et al.

LANCET (2010)

Add to Collection

Article Medicine, General & Internal

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.

Philip W. Kantoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Anatomy & Morphology

Lack of BRAF Activating Mutations in Prostate Adenocarcinoma A Study of 93 Cases

Ting Liu et al.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2009)

Add to Collection

Review Cell Biology

Mechanisms and functions of DNA mismatch repair

Guo-Min Li

CELL RESEARCH (2008)

Add to Collection

Review Cell Biology

The multifaceted mismatch-repair system

J Jiricny

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)

Add to Collection

Review Hematology

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

M Deininger et al.

BLOOD (2005)

Add to Collection

Article Medicine, General & Internal

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

IF Tannock et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

Review Neurosciences

Neurotrophins and their receptors: A convergence point for many signalling pathways

MV Chao

NATURE REVIEWS NEUROSCIENCE (2003)

Add to Collection

Article Multidisciplinary Sciences

Mutations of the BRAF gene in human cancer

H Davies et al.

NATURE (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.